Cycle-length evidence
Teriparatide cycle length: what human studies ran
FDA-approvedAHuman trial evidence
Short answer: Teriparatide has no "cycle". As an approved drug it is used as its label and a prescriber direct.
Treatment and follow-up in human studies
No human study durations are recorded.
What has not been tested
- On-and-off schedules or breaks between courses.
- Repeated courses and long-term exposure beyond the periods listed.
- Teriparatide combined with other compounds, unless a study above says so.
Frequently asked questions
Is there an established Teriparatide cycle length?
No cycle is defined. Teriparatide is an approved drug whose label describes treatment under a prescriber's care; the label, not a cycle, governs duration.
What is the longest human study of Teriparatide?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
References
- FORTEO (teriparatide injection), for subcutaneous use, prescribing information (DailyMed, effective 08/2026) FDA label (DailyMed). 2026
- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med. 2001
- Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial Lancet. 2018
- Drugs@FDA (openFDA) application records for teriparatide (NDA 021318 and others) U.S. FDA. 2026
- UniProtKB P01270, Parathyroid hormone (human) UniProt. 2026
- World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026
- PubChem compound record for teriparatide PubChem. 2026